National Storage Mechanism | Additional information

4basebio Plc - Directors' Dealings

PR Newswire

LONDON, United Kingdom, February 05

5 February 2024

4basebio plc

(“4babsebio” or the "Company")

Directors’ Dealings

Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces that, further to its announcement of 2 February 2024, directors of the Company have sold shares in order to pay for options exercised as follows:


Name	Number of Shares Sold	Sale price per share (p)	Shareholding Following Sale	Shareholding as a Percentage of Issued Share Capital
Heikki Lanckriet	45,322	660p	1,418,994	11.09%
David Roth	38,292	660p	457,708	3.58%

The calculations above are based on an issued share capital of the Company of 12,796,208 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:


4basebio PLC	+44 (0)12 2396 7943
Heikki Lanckriet, CEO

Cairn Financial Advisers LLP (Nominated Adviser)	+44 (0)20 7213 0880
Jo Turner / Sandy Jamieson

Cavendish Capital Markets Limited (Broker)	+44 (0)20 7220 0500
Geoff Nash/Charlie Beeson


Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	1. Dr Heikki Lanckriet 2. David Roth
2	Reason for notification
a.	Position/Status	1. CEO 2. CFO
b.	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	4basebio plc
b.	LEI	213800E2DX9EAIUNCB30
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BMCLYF79
b.	Nature of the transaction	Sale of Ordinary Shares
			Price(s) per share (p)	Volume(s)
1. 660p 2. 660p	45,322 38,292

d.	Aggregated information - Volume - Price	- 83,614 - 660 pence per share
e.	Date of the transaction	2/2/2024
f.	Place of the transaction	London Stock Exchange, AIM